K2M to Debut Balance ACS™ at Leading Spine Meetings in March 2017
08 Mars 2017 - 3:25PM
K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a
global leader of complex spine and minimally invasive solutions
focused on achieving three-dimensional Total Body Balance™, today
announced that it will debut the Balance ACS™ (or BACS™)
platform at the Annual Meeting of the American Association of
Neurological Surgeons/Congress of Neurological Surgeons Section on
Disorders of the Spine and Peripheral Nerves (AANS/CNS) and the
American Academy of Orthopaedic Surgeons Annual Meeting (AAOS). The
Company will also participate in the British Association of Spine
Surgeons (BASS) annual meeting, marking the international
introduction of the Balance ACS platform.
Balance ACS is a comprehensive platform applying
three-dimensional solutions across the entire clinical care
continuum to help drive quality outcomes in spine patients. BACS
provides solutions focused on achieving balance of the spine by
addressing each anatomical vertebral segment with a 360-degree
approach of the axial, coronal and sagittal planes, emphasizing
Total Body Balance as an important component of surgical
success.
During the meetings, K2M will demo the BACS System, which
provides the necessary services to facilitate quality surgical
outcomes and support the intraoperative process. The Company will
also unveil a BACS app, which serves as a convenient portal for
surgeons to access the BACS System, including:
- BACS Preauthorization: An easy-to-follow insurance
documentation tool that displays payer- and patient-specific
requirements.
- BACS Surgical Planner: A surgical image measuring technology to
assist in planning and preoperative implant selection.
- BACS Anatomical Modeling: 3D-printed anatomical models to aid
in visualization of patient anatomy for surgical planning and
intraoperative use.
- BACS Data Management: A data collection and operative reporting
system to track patient quality metrics achieved with spinal
balance.
“K2M is excited to introduce the Balance ACS platform of
three-dimensional solutions and host educational workshops at
leading spine conferences in the United States and
internationally,” said K2M President and CEO Eric Major. “Our
experience developing complex spine innovations and advancements in
3D solutions has led us to a comprehensive, next-generation BACS
platform to help surgeons achieve quality outcomes and Total Body
Balance for their patients.”
K2M Meeting Participation Details
K2M will showcase the Balance ACS platform and demo the BACS
System and the BACS app. The Company will also host physician
workshops featuring prominent spine surgeons presenting on the
latest research and clinical applications of the platform.
- Annual Meeting of the AANS/CNS Section on Disorders of
the Spine and Peripheral Nerves: March 8–10, Las Vegas, NV
- BACS Platform Exhibition and BACS App Demo: Booth #901
- Workshop: Techniques to Optimize Spinal Balance
- Friday, March 10, 2017; Noon–1 p.m. (PST); Marquis 6
- Faculty: Andrew Dailey, MD
- American Academy of Orthopaedic Surgeons Annual
Meeting: March 14–18, San Diego, CA
- BACS Platform Exhibition and BACS App Demo: Booth
#425
- British Association of Spine Surgeons: March
15–17, Manchester, UK
- BACS Platform Exhibition and BACS App Demo: Compass Room, Stand
#C9
- Workshop: Techniques to Optimize Spinal Balance
- Wednesday, March 15, 2017; 12:30–13:15; Aldridge Studio
- Faculty: Robert Lee, BSc, MBBS, FRCS
For more information about Balance ACS and K2M, visit
www.BACS.com and www.K2M.com.
About K2M
K2M Group Holdings, Inc. is a global leader of complex spine and
minimally invasive solutions focused on achieving three-dimensional
Total Body Balance. Since its inception, K2M has designed,
developed and commercialized innovative complex spine and minimally
invasive spine technologies and techniques used by spine surgeons
to treat some of the most complicated spinal pathologies. K2M has
leveraged these core competencies into Balance ACS, a platform of
products, services, and research to help surgeons achieve
three-dimensional spinal balance across the axial, coronal and
sagittal planes, with the goal of supporting the full continuum of
care to facilitate quality patient outcomes. The Balance ACS
platform, in combination with the Company’s technologies,
techniques and leadership in the 3D-printing of spinal devices,
enable K2M to compete favorably in the global spinal surgery
market. For more information, visit www.K2M.com and connect with us
on Facebook, Twitter, Instagram, LinkedIn, and YouTube.
Forward-Looking Statements This press release
contains forward-looking statements that reflect current views with
respect to, among other things, operations and financial
performance. Forward-looking statements include all
statements that are not historical facts such as our statements
about our expected financial results and guidance and our
expectations for future business prospects, including with respect
to our international distribution partners in Australia and
Japan. In some cases, you can identify these forward-looking
statements by the use of words such as "“outlook,” “guidance,”
“believes,” “expects,” “potential,” “continues,” “may,” “will,”
“should,” “could,” “seeks,” “predicts,” “intends,” “plans,”
“estimates,” “anticipates” or the negative version of these words
or other comparable words. Such forward-looking statements
are subject to various risks and uncertainties including, among
other things: our ability to achieve or sustain profitability in
the future; our ability to demonstrate to spine surgeons the merits
of our products; pricing pressures and our ability to compete
effectively generally; collaboration and consolidation in hospital
purchasing; in adequate coverage and reimbursement for our products
from third-party payors; lack of long-term clinical data supporting
the safety and efficacy of our products; dependence on a limited
number of third-party suppliers; our ability to maintain and expand
our network of direct sales employees, independent sales agencies
and international distributors and their level of sales or
distribution activity with respect to our products; proliferation
of physician-owned distributorships in the industry; decline in the
sale of certain key products; loss of key personnel; our ability to
enhance our product offerings through research and development; our
ability to manage expected growth; our ability to successfully
acquire or invest in new or complementary businesses, products or
technologies; our ability to educate surgeons on the safe and
appropriate use of our products; costs associated with high levels
of inventory; impairment of our goodwill and intangible assets;
disruptions in our main facility or information technology
systems; our ability to ship a sufficient number of our
products to meet demand; our ability to strengthen our brand;
fluctuations in insurance cost and availability; our ability to
comply with extensive governmental regulation within the United
States and foreign jurisdictions; our ability to maintain or
obtain regulatory approvals and clearances within the United States
and foreign jurisdictions; voluntary corrective actions by us or
our distribution or other business partners or agency enforcement
actions; recalls or serious safety issues with our products;
enforcement actions by regulatory agencies for improper marketing
or promotion; misuse or off-label use of our products; delays or
failures in clinical trials and results of clinical trials; legal
restrictions on our procurement, use, processing, manufacturing or
distribution of allograft bone tissue; negative publicity
concerning methods of tissue recovery and screening of donor
tissue; costs and liabilities relating to environmental laws and
regulations; our failure or the failure of our agents to
comply with fraud and abuse laws; U.S. legislative or Food and Drug
Administration regulatory reforms; adverse effects of medical
device tax provisions; potential tax changes in jurisdictions in
which we conduct business; our ability to generate significant
sales; potential fluctuations in sales volumes and our results of
operations over the course of the year; uncertainty in future
capital needs and availability of capital to meet our needs; our
level of indebtedness and the availability of borrowings under our
credit facility; restrictive covenants and the impact of other
provisions in the indenture governing our convertible senior
notes and our credit facility; continuing worldwide economic
instability; our ability to protect our intellectual property
rights; patent litigation and product liability lawsuits; damages
relating to trade secrets or non-competition or non-solicitation
agreements; risks associated with operating internationally;
fluctuations in foreign currency exchange rates; our ability to
comply with the Foreign Corrupt Practices Act and similar laws;
increased costs and additional regulations and requirements as a
result of being a public company; our ability to implement and
maintain effective internal control over financial reporting;
potential volatility in our stock due to sales of additional shares
by our pre-IPO owners or otherwise; our lack of current plans to
pay cash dividends; our ability to take advantage of certain
reduced disclosure requirements and exemptions as a result of being
an emerging growth company; potential dilution by the future
issuances of additional common stock in connection with our
incentive plans, acquisitions or otherwise; anti-takeover
provisions in our organizational documents and our ability to issue
preferred stock without shareholder approval; potential limits on
our ability to use our net operating loss carryforwards; and other
risks and uncertainties, including those described under the
section entitled “Risk Factors” in our most recent Annual Report on
Form 10-K filed with the SEC, as such factors may be updated from
time to time in our periodic filings with the SEC, which are
accessible on the SEC’s website at www.sec.gov. Accordingly,
there are or will be important factors that could cause actual
outcomes or results to differ materially from those indicated in
these statements. These factors should not be construed as
exhaustive and should be read in conjunction with the other
cautionary statements that are included in this release and our
filings with the SEC.
We operate in a very competitive and challenging
environment. New risks and uncertainties emerge from time to
time, and it is not possible for us to predict all risks and
uncertainties that could have an impact on the forward-looking
statements contained in this release. We cannot assure you
that the results, events and circumstances reflected in the
forward-looking statements will be achieved or occur, and actual
results, events or circumstances could differ materially from those
described in the forward-looking statements.
The forward-looking statements made in this press release relate
only to events as of the date on which the statements are
made. We undertake no obligation to publicly update or review
any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as required
by law. We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Unless specifically stated otherwise, our forward-looking
statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures, investments or
other strategic transactions we may make.
Media Contact:
Zeno Group on behalf of K2M Group Holdings, Inc.
Christian Emering, 212-299-8985
Christian.Emering@ZenoGroup.com
Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.
Mike Piccinino, CFA, 443-213-0500
K2M@westwicke.com
K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024